Annogen invited to speak at CropIB 2025

Crop improvement

We’re thrilled to share that our Founder & CEO, Joris van Arensbergen, has been invited to speak at the prestigious Crop Innovation and Business (CIB) Conference in Cologne, taking place from 30 March – 1 April 2025.

Joris will be delivering a talk on Large-scale identification of trait-associated regulatory elements and gain-of-function mutations for crop improvement.

This is an incredible opportunity to showcase how cutting-edge research can drive the future of sustainable and innovative crop development.

Annogen has previously worked with leading agbio including Bayer, BASF, KWS and Syngenta.

If you’re attending CropIB this year, don’t miss this insightful session where Joris will dive deep into the potential of leveraging regulatory elements and mutations to unlock new possibilities for crop improvement.

For more information and the full program, visit cropib.com.

 

 

 

 

 

 

 

 

​

 

 

 

 

 

 

 

 

​

 

 

 

 

 

 

 

 

​

 

 

 

 

VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2

VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2

Dec 11, 2025

VectorY Therapeutics has received clearance from the U.S. FDA to begin its PIONEER-ALS Phase 1/2 Trial for VTx-002. This is a special type of antibody therapy designed to fight the root cause of most ALS cases: a faulty protein called TDP-43 . The VTx-002 treatment uses a harmless virus (AAV5.2 capsid) to deliver instructions to the body’s cells, turning them into tiny factories that continuously produce the therapeutic antibody. This allows the treatment to keep working after just one dose. A key piece of the instruction manual that ensures this continuous production is the promoter, which acts like an “on” switch for the antibody gene, and this vital component was developed by Annogen. The study will test the safety of VTx-002, which is designed to clean up toxic TDP-43 and help sick motor neurons recover.

Annogen Heads to London for the Advanced Therapies Congress 2026

Annogen Heads to London for the Advanced Therapies Congress 2026

Dec 4, 2025

Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.

Technology

 

Solutions

 

Annogen

 

SuRE™

Survey for Regulatory Elements

AIM™

Annogen Integration Site Mapping

Cell & Gene Therapy

Promoter engineering

Off-the-shelf-promoters

Promoter optimization

Expression site identification

Crop Engineering

Functional genome analysis

Training Data Sets

Large-scale genomic data for AI/ML training

Manufacturing Cell Lines

Promoter engineering

Off-the-shelf-promoters

Promoter optimization

Expression site identification

Home

About us

News

Insights

Contact